Acorn Management Partners, LLC

05/07/2025

Our client here at Acorn, Xiao-I Corporation Expands Strategic Partnership with AIA China Through RMB 3-4 Million AI Solutions Deal.

04/21/2025

We are proud to share one of our clients here at Acorn, $CYBN Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs.

TORONTO, April 21, 2025--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic par...

04/15/2025

Our client here at Acorn, Perfect Corp. to Announce Financial Results for First Quarter of 2025 on April 28, 2025

NEW YORK, April 14, 2025--Perfect Corp. (NYSE: PERF) ("Perfect" or the "Company"), a global leader in providing augmented reality ("AR") and artificial intelligence ("AI") Software-as-a-Service ("SaaS") solutions to beauty and fashion industries, today announced that it plans to release its financia...

04/15/2025

Our client here at Acorn, Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

https://hubs.ly/Q03hs4mr0

04/07/2025

Our client $PERF Perfect Corp to Present at the LD Micro Invitational XV

https://hubs.ly/Q03g6Frb0

04/07/2025

Our client Zevra $ZVRA Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Revie...

03/19/2025

Our client AIXI, Xiao-I Corporation Announces Strategic Partnership with TF International to Advance AI-Powered Financial Services

Xiao-I Corporation (NASDAQ: AIXI), an advanced artificial intelligence company ("Xiao-I"), announced a global strategic partnership with TF International Securities Group Limited ("TF International"), a Hong Kong-based full-licensed financial institution under Hubei Hongtai Group and Tianfeng Securi...

03/07/2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans’ Administration Special Emphasis Panel on Precision Oncology Trial builds on promising clinical evidence supporting a PARP inhibitor a...

03/05/2025

Our client here at Acorn, Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program.

Boston (March 3, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary,...

02/20/2025

Xiao-I Corporation Unveils tAIkbox 1: Turning Frustrating Automated Calls into Exceptional Customer Service

Xiao-I Corporation (NASDAQ: AIXI), a trailblazer in artificial intelligence, today launched tAIkbox 1 in the U.S., a game-changing AI-powered device set to redefine customer service. Unlike the clunky, infuriating automated systems that leave callers shouting "customer service" in exasperation, tAIk...

02/19/2025

Clover Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. Management will host a conference call...